Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:

NCT ID: NCT04025957 Completed - Clinical trials for Advanced Malignancies

A Study of SHR-1501 in Patients With Advanced Tumors

Start date: October 30, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in patients with advanced malignancies .

NCT ID: NCT03995472 Completed - Clinical trials for Advanced Malignancies

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Start date: February 14, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.

NCT ID: NCT03907969 Completed - Clinical trials for Advanced Malignancies

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

Start date: October 9, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or novel anti-cancer agents in participants with advanced malignancies.

NCT ID: NCT03763149 Completed - Clinical trials for Advanced Malignancies

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas

Start date: February 19, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.

NCT ID: NCT03717103 Completed - Clinical trials for Advanced Malignancies

A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies

Start date: January 10, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.

NCT ID: NCT03474640 Active, not recruiting - Clinical trials for Advanced Malignancies

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Start date: March 14, 2018
Phase: Phase 1
Study type: Interventional

The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of Toripalimab, 2) evaluate antitumor activity of Toripalimab; 3) determine the immunogenicity of Toripalimab; 4) evaluate overall survival. The exploratory objectives are to: 1) evaluate biomarkers that may correlate with activity of Toripalimab, 2) evaluate pharmacodynamic effects of Toripalimab on its target receptor, programmed cell death 1 (PD-1), as well as effects on the immune system. 3) evaluate the utility of PD-L1 & additional exploratory markers as biomarkers that could aid in selection of appropriate subjects for TAB001 therapy, and 4) identification of additional biomarkers correlating with response to treatment with TAB001.

NCT ID: NCT03407976 Terminated - Clinical trials for Urothelial Carcinoma

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

APPEASE
Start date: June 19, 2018
Phase: Phase 1
Study type: Interventional

This is an open label nonrandomized Phase I/ IIA trial designed to assess the safety, tolerability, and efficacy of apatinib in combination with pembrolizumab. Phase I will assess the safety of combining increasing oral daily doses of apatinib with a fixed dose of IV pembrolizumab every three weeks and will determine the RP2D (Recommended Phase 2 Dose). Phase II will assess the efficacy of the RP2D of apatinib in combination with pembrolizumab and provide additional safety and tolerability data in three disease-specific cohorts

NCT ID: NCT03297424 Completed - Solid Tumor Clinical Trials

A Study of PLX2853 in Advanced Malignancies.

Start date: September 12, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

NCT ID: NCT03277352 Terminated - Metastatic Cancer Clinical Trials

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Start date: November 21, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.

NCT ID: NCT03241173 Completed - Clinical trials for Advanced Malignancies

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Start date: October 9, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.